Derivados adamantoides multialvos para a terapia da doença de Alzheimer: testes in vitro e in vivo em modelos animais não convencionais
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
Alzheimer's disease (AD) is characterized by the deposition of β-amyloid plaques and the
formation of neurofibrillary tangles of tau protein. Currently, in Brazil, only five drugs are
available for its treatment: donepezil, rivastigmine, galantamine (acetylcholinesterase inhibitors
- AChE), memantine (an N-methyl-D-aspartate receptor antagonist - NMDA), and donanemab
(an antiamyloidogenic monoclonal antibody). These treatments are unable to prevent neuronal
loss, temporarily avoiding the progression of the symptoms, making the search for more
effective compounds a priority. To contribute to this goal, the present work aimed to synthesize
and characterize seven adamantoid-aminated compounds with a hybrid molecular structure that
could interact with AChE and NMDAr. The synthesis of the organic compounds was carried
out in two steps: replacement of the hydroxyl group of adamantane-1-methanol with iodine,
followed by replacement of the iodine with the amino group. Characterization was performed
by nuclear magnetic resonance (NMR) and infrared vibrational spectroscopy (IR). The
compounds were evaluated in vitro for AChE inhibition capacity (Ellman test) and antioxidant
activity against 2,2-diphenyl-1-picrylhydrazyl (DPPH). Cytogenotoxicity was assessed by the
Allium cepa test and acute toxicity by the Artemia salina assay. Cytotoxicity was determined
in glial cells (U87) and mouse fibroblasts (L929) by the MTT test. The most promising
compound, N
1
-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1,4-butanediamine dihydrochloride
(AG03), was evaluated in vivo for neurological activity using different C. elegans strains. The
results indicated that the proposed synthetic route was technically feasible, allowing the obtain
pure compounds in good yields (50 to 85%). In vitro, they had high AChE inhibition capacity
(78 to 97%), but low antioxidant activity (less than 35%). The samples had different cytotoxic
effects against the cells used. Among the synthesized molecules, AG03 demonstrated the
greatest enzyme inhibition capacity (97% AChE), was not cytogenotoxic (at a concentration of
0.06 mg/L), and was not toxic to the larvae of the microcrustacean Artemia salina. Ultimately,
the compounds exhibit high AChE inhibition, and AG03 shows a multitarget effect, modulating
cholinergic and glutamatergic responses in in vivo assays. Therefore, this work represents a
relevant contribution to research on AD's treatments.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

